Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD
Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which develops drug candidates for the treatment of COPD, and other common diseases, announced today that they have signed an agreement for the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.COPD is considered one of the most common and fastest growing diseases that lack satisfactory treatment. The formulation work